U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Cutaneous B Lymphoblastic Leukemia/Lymphoma

MedGen UID:
313082
•Concept ID:
C1707589
•
Neoplastic Process
Synonyms: Cutaneous B-Lymphoblastic Leukemia/Lymphoma; Cutaneous Precursor B-Lymphoblastic Lymphoma/Leukemia

Definition

B-lymphoblastic leukemia/lymphoma that arises from the skin. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVCutaneous B Lymphoblastic Leukemia/Lymphoma

Professional guidelines

PubMed

Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT, Lewis DJ, Duvic M
Expert Rev Hematol 2017 Sep;10(9):757-760. Epub 2017 Aug 21 doi: 10.1080/17474086.2017.1361819. PMID: 28756726
Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).
Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, McMillan A; British Committee for Standards in Haematology
Br J Haematol 2011 May;153(4):451-85. Epub 2011 Apr 11 doi: 10.1111/j.1365-2141.2011.08651.x. PMID: 21480860
Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K, Dearden CE
Expert Rev Anticancer Ther 2008 Apr;8(4):525-33. doi: 10.1586/14737140.8.4.525. PMID: 18402519

Recent clinical studies

Etiology

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
Pediatric Cutaneous Hematologic Disorders: Cutaneous Lymphoma and Leukemia Cutis-Experience of a Tertiary-Care Pediatric Institution and Review of the Literature.
Colmant C, Demers MA, Hatami A, Coulombe J, McCuaig CC, Piram M, Marcoux D, Kokta V, Powell J
J Cutan Med Surg 2022 Jul-Aug;26(4):349-360. Epub 2022 Feb 15 doi: 10.1177/12034754221077694. PMID: 35167768
Primary Cutaneous Lymphomas in Children and Adolescents.
Ceppi F, Pope E, Ngan B, Abla O
Pediatr Blood Cancer 2016 Nov;63(11):1886-94. Epub 2016 May 27 doi: 10.1002/pbc.26076. PMID: 27229270
Coexistent cutaneous T-cell lymphoma and B-cell malignancy. French Study Group on Cutaneous Lymphomas.
Grange F, Avril MF, Esteve E, Joly P, Bosq J, de Murets A, Thomine E, Ortoli JC, Duvillard P, Vaillant L
J Am Acad Dermatol 1994 Nov;31(5 Pt 1):724-31. doi: 10.1016/s0190-9622(94)70232-2. PMID: 7929916
Cutaneous B-cell lymphoma.
Burg G, Kaudewitz P, Klepzig K, Przybilla B, Braun-Falco O
Dermatol Clin 1985 Oct;3(4):689-704. PMID: 3916175

Diagnosis

Follicular lymphoma and marginal zone lymphoma: how many diseases?
Laurent C, Cook JR, Yoshino T, Quintanilla-Martinez L, Jaffe ES
Virchows Arch 2023 Jan;482(1):149-162. Epub 2022 Nov 17 doi: 10.1007/s00428-022-03432-2. PMID: 36394631Free PMC Article
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L
Am J Clin Dermatol 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. PMID: 32613545
Cutaneous B-Cell Lymphoblastic Lymphoma.
Amarasekera D, Connolly D, Gochoco A, Yang S, Grosso D, Flomenberg N, Shi W, Alpdogan SO, Duffy R, Sahu J
Am J Dermatopathol 2019 Aug;41(8):596-601. doi: 10.1097/DAD.0000000000001347. PMID: 31335415
Primary Cutaneous Lymphomas in Children and Adolescents.
Ceppi F, Pope E, Ngan B, Abla O
Pediatr Blood Cancer 2016 Nov;63(11):1886-94. Epub 2016 May 27 doi: 10.1002/pbc.26076. PMID: 27229270
Cutaneous B-cell lymphoma.
Burg G, Kaudewitz P, Klepzig K, Przybilla B, Braun-Falco O
Dermatol Clin 1985 Oct;3(4):689-704. PMID: 3916175

Therapy

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L
Am J Clin Dermatol 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. PMID: 32613545
Cutaneous B-Cell Lymphoblastic Lymphoma.
Amarasekera D, Connolly D, Gochoco A, Yang S, Grosso D, Flomenberg N, Shi W, Alpdogan SO, Duffy R, Sahu J
Am J Dermatopathol 2019 Aug;41(8):596-601. doi: 10.1097/DAD.0000000000001347. PMID: 31335415
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H
Exp Mol Med 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. PMID: 31221981Free PMC Article
Alemtuzumab.
Ravandi F, O'Brien S
Expert Rev Anticancer Ther 2005 Feb;5(1):39-51. doi: 10.1586/14737140.5.1.39. PMID: 15757437

Prognosis

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group
Lancet Haematol 2022 Nov;9(11):e833-e843. Epub 2022 Oct 10 doi: 10.1016/S2352-3026(22)00245-9. PMID: 36228643
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L
Am J Clin Dermatol 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. PMID: 32613545
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H
Exp Mol Med 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. PMID: 31221981Free PMC Article
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Ransohoff JD, Kwong BY
Clin Lymphoma Myeloma Leuk 2017 Dec;17(12):834-851. Epub 2017 Jul 14 doi: 10.1016/j.clml.2017.07.005. PMID: 28918995
Coexistent cutaneous T-cell lymphoma and B-cell malignancy. French Study Group on Cutaneous Lymphomas.
Grange F, Avril MF, Esteve E, Joly P, Bosq J, de Murets A, Thomine E, Ortoli JC, Duvillard P, Vaillant L
J Am Acad Dermatol 1994 Nov;31(5 Pt 1):724-31. doi: 10.1016/s0190-9622(94)70232-2. PMID: 7929916

Clinical prediction guides

Cutaneous lymphoma in Japan, 2012-2017: A nationwide study.
Fujii K, Hamada T, Shimauchi T, Asai J, Fujisawa Y, Ihn H, Katoh N
J Dermatol Sci 2020 Mar;97(3):187-193. Epub 2020 Jan 25 doi: 10.1016/j.jdermsci.2020.01.010. PMID: 32033869
Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M, Huang X, Ye X, Qian W
Int Immunopharmacol 2019 Dec;77:105999. Epub 2019 Nov 6 doi: 10.1016/j.intimp.2019.105999. PMID: 31704289
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H
Exp Mol Med 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. PMID: 31221981Free PMC Article
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Ransohoff JD, Kwong BY
Clin Lymphoma Myeloma Leuk 2017 Dec;17(12):834-851. Epub 2017 Jul 14 doi: 10.1016/j.clml.2017.07.005. PMID: 28918995
Immunologic markers in non-Hodgkin's lymphoma.
Freedman AS, Nadler LM
Hematol Oncol Clin North Am 1991 Oct;5(5):871-89. PMID: 1938759

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...